Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Goserelin and AI for Premenopausal ER+ HER2- Breast Cancer
NCT01368263Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2011
- Primary completion
- May 2013
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of goserelin, letrozole, anastrozole in breast cancer, sponsored by Washington University School of Medicine. Started Sep 2011; status: terminated.
02
Drugs
goserelinletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01368263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01368263.